Armodafinil (US brand name Nuvigil®) is a wakefulness-promoting agent. Here is key information about this medication.
FDA-approved indications
To improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work disorder
Dosage
1. Adults
Narcolepsy or OSA: 150 mg to 250 mg once daily in the morning
Shift work disorder: 150 mg once a day taken approximately one hour prior to start of the work shift
2. Geriatric patients
Consider lower doses
3. Patients with severe hepatic impairment
Dosage should be reduced
Drug interactions caused by armodafinil (Nuvigil®)
Induces CYP3A4/5. Therefore, may reduce levels of steroidal contraceptives, cyclosporine, midazolam, triazolam, etc.
Inhibits CYP2C19. Therefore, may increase levels of phenytoin, diazepam, propranolol, omeprazole, clomipramine, etc.
When armodafinil is used with warfarin, PT/ INR should be monitored more frequently.
Armodafinil should be used with MAO inhibitors only with great caution.
Dosage forms and strengths
Tablet: 50 mg, 150 mg, 200 mg, and 250 mg
Please refer to Prescribing Information (see link below) for a complete discussion of dosage, administration, warnings and precautions, contraindications, etc.
Related Pages
Modafinil (Provigil®): Basic Information
How to screen for sleep apnea: Main page
How to know if your patient snores if s/he sleeps alone!
References
Prescribing Information for Armodafinil (Nuvigil®)
Copyright 2016 to 2022, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, r as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: